The vast majority of immune cells are found in the gut but historically, the gut has been viewed as a liability to drug development. The question of whether or not greater understanding of harnessing the gut could drive more promising drug development has led to the formation of a new company, Kintai Therapeutics.
View article: https://www.biospace.com/article/exclusive-flagship-ventures-company-kintai-therapeutics-focuses-on-enteric-therapeutics/
© Paul Peter Tak.
All rights reserved.